Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 Apr;87(4):396-8. doi: 10.1038/clpt.2010.1.

Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?

Author information

1
Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. mark.febbraio@bakeridi.edu.au

Abstract

Interleukin-6 (IL-6) has been linked to a myriad of diseases associated with inflammation, including rheumatoid arthritis (RA), Crohn's disease, and several types of cancer. In 2009 the US Food and Drug Administration accepted a complete-response submission for the use of Actemra (tocilizumab), the first humanized IL-6 receptor-inhibiting monoclonal antibody, for the treatment of RA. Although this treatment will certainly help in managing inflammatory disorders such as RA, we suggest that side effects of such blockade may be excess weight gain and hyperlipidemia.

PMID:
20305672
DOI:
10.1038/clpt.2010.1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center